Efficacy of iloperidone in schizophrenia: A PANSS five-factor analysis

Schizophrenia Research

Volumn 131, Issue 1-3, 2011, Pages 75-81

  Citrome, Leslie ^a   Meng, Xiangyi ^b   Hochfeld, Marla ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Factor; Iloperidone; PANSS; Schizophrenia

Indexed keywords

HALOPERIDOL; ILOPERIDONE; PLACEBO; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ANXIETY; ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXCITEMENT; FACTORIAL ANALYSIS; FEMALE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR ANALYSIS, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MOOD DISORDERS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051800301     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.018     Document Type: Article

References (18)

1. Citrome L. Iloperidone for schizophrenia: A review of the efficacy and safety profile for this newly-commercialised second-generation antipsychotic. Int. J. Clin. Pract. 2009, 63(8):1237-1248.
2. Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int. J. Clin. Pract. 2010, 64(6):707-718.
3. Cutler A.J., Kalali A.H., Weiden P.J., Hamilton J., Wolfgang C.D. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J. Clin. Psychopharmacol. 2008, 28(2 Suppl 1):S20-S28.
4. Kane J.M., Lauriello J., Laska E., DiMarino M., Wolfgang C.D. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J. Clin. Psychopharmacol. 2008, 28(2 Suppl 1):S29-S35.
5. Kane J.M., Cohen M., Zhao J., Alphs L., Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J. Clin. Psychopharmacol. 2010, 30(2):106-115.
6. Kantrowitz J.T., Citrome L. Schizoaffective disorder, a review of current research themes and pharmacologic management. CNS Drugs 2011, 25(4):317-331.
7. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
8. Lançon C., Aghababian V., Llorca P.M., Auquier P. Factorial structure of the Positive and Negative Syndrome Scale (PANSS): a forced five-dimensional factor analysis. Acta Psychiatr. Scand. 1998, 98(5):369-376.
9. Lehoux C., Gobeil M.H., Lefebvre A.A., Maziade M., Roy M.A. The Five-Factor Structure of the PANSS: A Critical Review of its Consistency Across Studies. Clin. Schizophr. Relat. Psychoses 2009, 3(2):103-110.
10. Levine S.Z., Rabinowitz J. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. J. Clin. Psychopharmacol. 2007, 27(5):431-436.
11. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S. A newfive factor model of schizophrenia. Psychiatr. Q. 1994, 65(4):299-322.
12. Lindenmayer J.P., Czobor P., Volavka J., et al. Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia. J. Clin. Psychiatry 2004, 65(4):551-556.
13. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58(12):538-546.
14. Novartis Pharmaceuticals Corporation Fanapt (iloperidone) Tablets. Revised 4/2011 (accessed 03 June 2011). http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf.
15. Olie J.P., Spina E., Murray S., Yang R. Ziprasidone and amisulpride effectively treat negative symptoms: results of a 12-week, double-blind study. Int. Clin. Psychopharamacol. 2006, 21(3):143-151.
16. Potkin S.G., Litman R.E., Torres R., Wolfgang C.D. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J. Clin. Psychopharmacol. 2008, 28(2 Suppl 1):S4-S11.
17. Van den Oord E.J., Rujescu D., Robles J.R., et al. Factor structure and external validity of the PANSS revisited. Schizophr. Res. 2006, 82(2-3):213-223.
18. White L., Harvey P.D., Opler L., Lindenmayer J.P. Empirical assessment of the factorial structure of clinical in schizophrenia.A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 1997, 30(5):263-274.